Physician profile
David J Schultz
NPI 1568436301
$18,641.26
in general payments reported to CMS, 2019-2025
32 companies · $314 in 2025
The $314 reported for 2025 was less than what a typical Interventional Cardiology provider received nationally (typical 2025 total: $1,092).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $14K · 2020: $715 · 2021: $947 · 2022: $1,026 · 2023: $890 · 2024: $690 · 2025: $314.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $1,894.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $1,893.95 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Amgen INC. | $13,657.06 | 2019-2025 | Repatha, Repatha |
| Novartis Pharmaceuticals Corporation | $1,966.56 | 2019-2025 | |
| Janssen Pharmaceuticals, INC | $616.52 | 2019-2024 | Xarelto |
| Pfizer INC. | $318.52 | 2019-2024 | |
| Merck Sharp & Dohme LLC | $260.82 | 2022-2025 | Verquvo |
| Astrazeneca Pharmaceuticals Lp | $260.00 | 2019-2022 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $255.98 | 2019-2025 | Jardiance |
| Sanofi-Aventis U.S. LLC | $179.89 | 2019-2023 | |
| Zoll Services LLC (A/K/A Zoll Lifecor Corp) | $155.08 | 2019-2023 | Lifevest |
| E.R. Squibb & Sons, L.L.C. | $151.22 | 2019-2025 | Camzyos |
| Abbott Laboratories | $144.71 | 2020-2024 | Perclose Prostyle, Jot Dx |
| Irhythm Technologies, INC. | $70.27 | 2021-2023 | Zio Xt Patch |
| Inari Medical, INC. | $56.62 | 2022-2024 | Ct Thrombectomy System Kit, Flowtriever Catheter, S |
| Kowa Pharmaceuticals America, INC. | $52.96 | 2019-2021 | |
| Amarin Pharma, INC. | $52.60 | 2019-2020 |
Show all 32 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Impulse Dynamics (USA) INC. | $45.16 | 2022 | |
| Astellas Pharma US INC | $42.83 | 2019-2020 | |
| Boston Scientific Corporation | $36.04 | 2025 | Varithena Administration Pack |
| Medtronic, INC. | $35.72 | 2024 | Venaseal |
| Akcea Therapeutics, INC. | $33.75 | 2020-2021 | |
| Vifor Pharma, INC. | $29.07 | 2019-2021 | |
| Esperion Therapeutics, INC. | $26.96 | 2020-2024 | Nexletol |
| Reflow Medical INC | $22.65 | 2024 | |
| Regeneron Healthcare Solutions, INC. | $22.46 | 2023 | Evkeeza |
| Novo Nordisk INC | $21.65 | 2025 | Wegovy |
| Glaxosmithkline, LLC. | $21.50 | 2025 | Shingrix, Arexvy |
| Bayer Healthcare Pharmaceuticals INC. | $20.54 | 2025 | |
| Lundbeck LLC | $18.46 | 2019 | |
| Otsuka America Pharmaceutical, INC. | $16.72 | 2019 | |
| Scpharmaceuticals INC. | $16.62 | 2023 | |
| Alnylam Pharmaceuticals INC. | $16.18 | 2021 | |
| Corcept Therapeutics | $16.14 | 2025 | Korlym |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw David Schultz listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.